HomeNewsSeysara Accredited for the Remedy of Average to Extreme Pimples Vulgaris
Posted in News on 3rd October 2018
Seysara is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic

Seysara is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic

The Food and Drug Administration (FDA) has approved Seysara (sarecycline; Almirall, S.A.) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ≥9 years old.

Seysara is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic. The approval was based on data from 2 large, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials involving patients with moderate to severe facial acne vulgaris.

Results showed that compared to placebo, sarecycline 1.5mg/kg once daily significantly improved acne severity (based on Investigator’s Global Assessment success) and significantly reduced inflammatory lesion count at Week 12. “The results of the studies are encouraging, with statistically significant efficacy vs placebo as early as 3 weeks,” said Dr Leon Kircik, a dermatologist from Louisville, Kentucky and a sarecycline clinical trialist.

Seysara is expected to launch in January 2019.

Related Post for New antibody can scale back swelling assaults in sufferers with hereditary angioedema

Botulinum toxin injections present promise to suppress postoperative atrial fibrillation
FDA: Critical Aspect Impact of AML Drug Not Being Acknowledged
New ointment for treating brown recluse spider bites is examined on people
FDA: MS Drug Linked to Circumstances of Stroke, Blood Vessel Wall Tears
New antibody can scale back swelling assaults in sufferers with hereditary angioedema